Document is current
Any future updates will be listed below
-
Authors
Gammelgaard, Odd L. http://orcid.org/0000-0002-5911-7276
Terp, Mikkel G. http://orcid.org/0000-0002-4468-6900
Kirkin, Alexei F.
Johansen, Simone http://orcid.org/0000-0002-6140-9366
Traynor, Sofie http://orcid.org/0000-0003-2565-5110
Vever, Henriette
Guldberg, Per http://orcid.org/0000-0002-4424-4803
Kodahl, Annette R. http://orcid.org/0000-0003-0515-9144
Gjerstorff, Morten F. http://orcid.org/0000-0002-0845-1952
Ditzel, Henrik J. http://orcid.org/0000-0003-3927-5135
-
Funding
Funding for this research was provided by:
Grosserer M. Brogaard og Hustrus Mindefond
Dagmar Marshalls Fond
A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond
Else og Mogens Wedell Wedellsborgs Fond
Fabrikant Einar Willumsens Mindelegat
Tornøes og Høyrups Fond
The Danish Cancer Society
The National Board of Health
The Region of Southern Denmark Research Counsel
CytoVac
Kornerup Fonden
University of Southern Denmark
- License Information
-
More Information
Article History
Received: 1 June 2023
Accepted: 11 December 2023
First Online: 6 January 2024
Declarations
:
: TNBC specimens from three patients were collected after informed consent was obtained from all patients. This study was carried out according to the principles of the Helsinki Declaration and approved by the National Ethical Committee of Denmark (no. S-1906975). All animal experiments were approved by the Experimental Animal Committee of The Danish Ministry of Justice (2021–15-0201–00843).
: Not applicable.
: AFK is a co-founder and an employee of Cytovac A/S, a biotechnology company that commercializes the ALECSAT therapy. AFK is co-inventors on a patent on ALECSAT and owns warrants and stock in Cytovac A/S. OGA, AFK and HJD are co-inventors of a patent application related to combined ALECSAT and anti-PDL1 therapy. The other authors declare no conflicts of interest.
